Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer.
- Author:
Peng YUAN
1
;
Ye XU
;
Tao OUYANG
;
Tian-feng WANG
;
Zhao-qing FAN
;
Tie FAN
;
Ben-yao LIN
;
Yun-tao XIE
;
Jin-feng LI
Author Information
- Publication Type:Journal Article
- MeSH: Adenomatous Polyposis Coli Protein; genetics; metabolism; Adult; Aged; Anthracyclines; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; BRCA1 Protein; genetics; metabolism; Breast Neoplasms; drug therapy; genetics; metabolism; pathology; CpG Islands; genetics; Cyclophosphamide; therapeutic use; DNA Methylation; Epirubicin; therapeutic use; Female; Fluorouracil; therapeutic use; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Young Adult
- From: Chinese Journal of Oncology 2009;31(4):282-286
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the correlation of hypermethylation of BRCA1 and APC gene promoters with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer.
METHODSOne hundred and forty patients with primary breast cancer received anthracycline-based neoadjuvant chemotherapy, and pretreatment hypermethylation status of BRCA1 and APC genes promoters was detected by methylation-specific PCR.
RESULTSOf the 140 patients, 30 (21.4%) achieved pathological complete response (pCR), and methylation rates of BRCA1 and APC gene promoters were 21.4% (30/140) and 18.3% (24/131), respectively. Among the 110 patients with unmethylated BRCA1 gene, 28 (25.5%) achieved pCR, while in the 30 patients with methylated BRCA1 gene, only 2 (6.7%) had a pCR, with a significant difference between the two groups (chi(2) = 4.94, P = 0.026). However, no statistically significant correlation was found between the methylation of APC gene and pCR to neoadjuvant chemotherapy in this cohort of patients (P > 0.05).
CONCLUSIONPrimary breast cancer with an unmethylated BRCA1 gene is prone to achieve a pathological complete response to anthracycline-based neoadjuvant chemotherapy than those with a methylated BRCA1 gene. BRCA1 methylation status may be a useful predictor for anthracycline-based neoadjuvant chemotherapy in primary breast cancer patients.
